Investigational drug · Phase 3
Lucerastat
Not approved by FDA. In 2 industry-sponsored Phase 2 or 3 trials that are active or finished in the last two years, most often for Fabry Disease.
Phase 3Last checked: Nov 19, 2026Latest source record: Nov 3, 2026 (newest trial update)Source: ClinicalTrials.govMethods & limitations
Highest phase
Phase 3
Industry-sponsored trials
Phase 2 and 3 trials
2
1 still active
All registered trials
33
Any phase or sponsor naming "Lucerastat"
First trial start
2018
Dec 18, 2018
Sponsors
Lead sponsors of its Phase 2 and 3 trials.
All registered trials by phase
Every ClinicalTrials.gov drug study naming "Lucerastat", any sponsor or status.
Conditions studied
As listed on its trial records.
- Fabry Disease
Approved drugs for the same conditions: Fabry disease · Rare and genetic disease
Largest trials
Live from ClinicalTrials.gov: studies naming "Lucerastat" as an intervention, largest first.
Amicus TherapeuticsIndustry
NCT06906367 · 450 participants (planned) · Start Feb 13, 2026 · Primary completion Jun 2032
Drug: migalastat HCl; ERT · For: Fabry Disease
Sites: Birmingham, Alabama; Little Rock, Arkansas; Atlanta, Georgia · 8 sites in all
- Efficacy and Safety of Lucerastat Oral Monotherapy in Adult Subjects With Fabry DiseasePivotal-lookingCompleted
Idorsia Pharmaceuticals Ltd.Industry
NCT03425539 · 118 participants · Start Jun 21, 2018 · Primary completion Aug 17, 2021
Drug: Lucerastat; Placebo · For: Fabry Disease
Sites: Birmingham, Alabama; Irvine, California; Oakland, California · 49 sites in all
- A Study to Evaluate the Long-term Safety and Tolerability of Lucerastat in Adult Subjects With Fabry DiseasePivotal-lookingCompleted
Idorsia Pharmaceuticals Ltd.Industry
NCT03737214 · 107 participants · Start Dec 18, 2018 · Primary completion Aug 31, 2026
Drug: Lucerastat · For: Fabry Disease
Sites: Birmingham, Alabama; Irvine, California; Oakland, California · 42 sites in all
- A Study to Evaluate the Effect of Venglustat Tablets on Left Ventricular Mass Index in Male and Female Adult Participants With Fabry DiseasePivotal-lookingActive, not recruiting
SanofiSanofi (SNY)
NCT05280548 · 104 participants · Start May 3, 2022 · Primary completion May 22, 2026
Drug: Venglustat (GZ402671); Agalsidase alfa and 2 more · For: Fabry Disease
Sites: Birmingham, Alabama; Los Angeles, California; Atlanta, Georgia · 54 sites in all
- Open-Label Phase 3 Long-Term Safety Study of MigalastatPivotal-lookingTerminated
Amicus TherapeuticsIndustry
NCT01458119 · 85 participants · Start Oct 14, 2011 · Primary completion Feb 17, 2016
Drug: migalastat hydrochloride · For: Fabry Disease
Sites: Atlanta, Georgia; Chicago, Illinois; Kansas City, Kansas · 25 sites in all
- Open-Label Extension Study of the Long-Term Effects of Migalastat HCL in Patients With Fabry DiseasePivotal-lookingCompleted
Amicus TherapeuticsIndustry
NCT02194985 · 84 participants · Start Mar 14, 2015 · Primary completion Oct 23, 2019
Drug: migalastat HCl 150 mg · For: Fabry Disease
Sites: Atlanta, Georgia; Kansas City, Kansas; Grand Rapids, Michigan · 28 sites in all
- Study to Compare the Efficacy and Safety of Oral AT1001 and Enzyme Replacement Therapy in Patients With Fabry DiseasePivotal-lookingCompleted
Amicus TherapeuticsIndustry
NCT01218659 · 68 participants · Start Sep 8, 2011 · Primary completion May 27, 2014
Drug: migalastat hydrochloride; agalsidase · For: Fabry Disease
Sites: Los Angeles, California; Aurora, Colorado; Decatur, Georgia · 25 sites in all
- Study of the Effects of Oral AT1001 (Migalastat Hydrochloride) in Patients With Fabry DiseasePivotal-lookingCompleted
Amicus TherapeuticsIndustry
NCT00925301 · 67 participants · Start Oct 23, 2009 · Primary completion Jun 12, 2012
Drug: migalastat hydrochloride; Placebo · For: Fabry Disease
Sites: Los Angeles, California; San Francisco, California; Decatur, Georgia · 28 sites in all
Idorsia Pharmaceuticals Ltd.Industry
NCT03832452 · 44 participants · Start Feb 14, 2019 · Primary completion Apr 22, 2019
Drug: Lucerastat (Treatment A); Moxifloxacin and 2 more · For: Healthy
Sites: Groningen, Netherlands
- A Study to Assess the Safety and Pharmacokinetics of Lucerastat (OGT 923) in Healthy SubjectsCompleted
Idorsia Pharmaceuticals Ltd.Industry
NCT02944487 · 39 participants · Start Oct 2002 · Primary completion Dec 2002
Drug: Lucerastat; Placebo · For: Healthy Subjects
Sites: Tranent, United Kingdom
Newest research
PubMed records naming it or its code names, newest first.
- Comment on "Population Pharmacokinetic Modeling for the Iminosugar Lucerastat Supports Dose Adaptation in Patients with Fabry Disease and Moderate to Severe Renal Function Impairment".
Akhtar A, Roman UH · J Clin Pharmacol 2026
- Population Pharmacokinetic Modeling for the Iminosugar Lucerastat Supports Dose Adaptation in Patients With Fabry Disease and Moderate to Severe Renal Function Impairment.
Brussee JM, Dingemanse J, Lott D, et al. · J Clin Pharmacol 2026
- Lucerastat, an oral therapy for Fabry disease: results from a pivotal randomized phase 3 study and its open-label extension.
Nordbeck P, Goker-Alpan O, Bernat JA, et al. · Nat Commun 2026
- Assessment of repurposed compounds against coronaviruses highlights the antiviral broad-spectrum activity of host-targeting iminosugars and confirms the activity of potent directly acting antivirals.
Brun J, Arman BY, Hill ML, et al. · Antiviral Res 2025
- New Drugs Available for Fabry Disease.
Perretta F, Cabrera G, Politei J · Kidney Blood Press Res 2025
- Fabry Disease: Current and Novel Therapeutic Strategies. A Narrative Review.
Palaiodimou L, Kokotis P, Zompola C, et al. · Curr Neuropharmacol 2023
Also in development for Fabry Disease
- VenglustatGZ402671Phase 35 trials
Sanofi · Fabry Disease, Gaucher's Disease Type III, Gaucher Disease Type 1
- 4D-310Phase 22 trials
4D Molecular Therapeutics · Fabry Disease
- AMT-191Phase 21 trial
UniQure Biopharma B.V. · Fabry Disease
- EXG110Phase 21 trial
Guangzhou Jiayin Biotech Ltd · Fabry Disease
- ST-920Phase 21 trial
Sangamo Therapeutics · Fabry Disease
Names are merged from how sponsors list this drug on ClinicalTrials.gov, so an alias can occasionally belong to a related compound. Development status changes faster than registry records do.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.